Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [11457]

Circular peptides in violets may aid in the fight against glioblastoma

Circular peptides in violets may aid in the fight against glioblastoma

Trial supports radiotherapy and cisplatin should remain the standard of care for p16+ oropharyngeal cancer

Trial supports radiotherapy and cisplatin should remain the standard of care for p16+ oropharyngeal cancer

Trial implies the addition of atezolizumab concurrently to standard of care does not improve survival in limited-stage small cell lung cancer

Trial implies the addition of atezolizumab concurrently to standard of care does not improve survival in limited...

Radon, even at levels below EPA guideline for mitigation, is linked to childhood leukemia

Radon, even at levels below EPA guideline for mitigation, is linked to childhood leukemia

Strategy to combat breast cancer involves two-pronged attack on enzyme that ‘feeds’ tumour

Strategy to combat breast cancer involves two-pronged attack on enzyme that ‘feeds’ tumour

People who experience side effects from cranial radiation therapy may recover full neurocognitive function within months

People who experience side effects from cranial radiation therapy may recover full neurocognitive function within...

Radiopharmaceutical therapy offers promise for people with tough-to-treat meningioma brain tumours

Radiopharmaceutical therapy offers promise for people with tough-to-treat meningioma brain tumours

FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations

FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19...

Oestrogens play a hidden role in cancers, inhibiting a key immune cell

Oestrogens play a hidden role in cancers, inhibiting a key immune cell

FDA approves selpercatinib for RET fusion-positive medullary thyroid cancer

FDA approves selpercatinib for RET fusion-positive medullary thyroid cancer

More from ecancer